Skip to main content
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Main navigation - Mobile
Medicare's new CAR-T coverage rules could boost adoption
Thursday, August 8, 2019
New CMS rules have removed some restrictions on healthcare providers that could in turn boost uptake of Gilead's and Novartis' CAR-T drugs.
Drugmakers settle with feds over charity contributions
Friday, April 5, 2019
Jazz, Lundbeck and Alexion inked settlements over allegations their contributions to patient charities were designed to boost sales.
Trump's budget amps up message on familiar drug pricing goals
Tuesday, March 12, 2019
Measures in Trump's 2020 budget aim to incentivize lower list prices, promote competition and more.
PhRMA ads target proposals to revamp Medicare drug coverage
Beth Snyder Bulik
Monday, March 11, 2019
A new ad campaign from the pharma industry's trade group weighs in on proposed changes to Medicare.
Aimovig angst overshadows Amgen’s otherwise solid quarter
Wednesday, October 31, 2018
Amgen declared the launch of migraine drug Aimovig an unqualified success, but analysts weren't quite ready to buy in to the euphoria.
As elections near, PhRMA's plowing $21M-plus into lobbying
Tuesday, October 23, 2018
Pharma has come under political pressure in Washington, D.C., and lobby spending figures indicate the industry is taking the threat seriously.
UnitedHealthcare favors biosims for its Medicare plans
Monday, October 15, 2018
After a CMS rule change in August, UnitedHealthcare is introducing step therapy in Medicare Advantage plans to favor biosimilars over certain brands.
Medicare Part B changes to hit Amgen, Regeneron: analysts
Friday, August 10, 2018
Federal officials unveiled changes to Medicare Part B this week that could result in lower sales for Amgen and Regeneron.
Pharma unleashes lobbying power to fight higher Part D discounts
Thursday, February 15, 2018
PhRMA called new donut-hole drug discounts a "massive bailout" for payers, but the insurance lobby says pharma's arguments are "ridiculous."